Somatostatin receptors in gastroenteropancreatic neuroendocrine tumours

W W de Herder, L J Hofland, A J van der Lely and S W J Lamberts

Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands

(Requests for offprints should be addressed to W W de Herder; Email: w.w.deherder@erasmusmc.nl)

Abstract

Five somatostatin receptor (sst) subtype genes, sst₁, sst₂, sst₃, sst₄ and sst₅, have been cloned and characterised. The five sst subtypes all bind natural somatostatin-14 and somatostatin-28 with high affinity. Endocrine pancreatic and endocrine digestive tract tumours also express multiple sst subtypes, but sst₂ predominance is generally found. However, there is considerable variation in sst subtype expression between the different tumour types and among tumours of the same type. The predominant expression of sst₂ receptors on pancreatic endocrine or carcinoid tumours is essential for the control of hormonal hypersecretion by the octapeptide somatostatin analogues such as octreotide and lanreotide. Somatostatin and its octapeptide analogues are also able to inhibit proliferation of normal and tumour cells. The high density of sst₂ or sst₅ on pancreatic endocrine or carcinoid tumours further allows the use of radiolabelled somatostatin analogues for *in vivo* visualisation. The predominant expression of sst₂ receptors in these tumours and the efficiency of sst₂ receptors to undergo agonist-induced internalisation is also essential for the application of radiolabelled octapeptide somatostatin analogues. Currently, [¹¹¹In-DTPA⁰]octreotide, [⁹⁰Y-DOTA⁰,Tyr³]octreotide, [¹⁷⁷Lu-DOTA⁰Tyr³]octreotate, [¹¹¹In-DOTA⁰]lanreotide and [⁹⁰Y-DOTA⁰]lanreotide can be used for this purpose.

Endocrine-Related Cancer (2003) 10 451–458

Somatostatin

Somatostatin is a small cyclic peptide. It circulates in the blood in two biologically active forms: somatostatin-14, consisting of 14 amino acids and somatostatin-28, consisting of 28 amino acids (Reichlin 1983*a,b*). Somatostatin is formed by proteolytic processing of larger precursor molecules: prepro-somatostatin and pro-somatostatin. This peptide was detected accidentally during studies of the distribution of growth hormone-releasing factor in the hypothalamus of rats (Krulich *et al.* 1968, Brazeau *et al.* 1973). Somatostatin inhibits a variety of physiological functions in the gastrointestinal tract, such as gastrointestinal motility, gastric acid production, pancreatic enzyme secretion, bile secretion and colonic fluid secretion. It also inhibits the secretion of pancreatic and intestinal hormones such as insulin, glucagon, secretin and vasoactive intestinal polypeptide. In addition to playing an important regulatory role in neurotransmission and secretion, the peptide may control cell proliferation in normal tissues and tumours (Reichlin 1983*a,b*, Schally 1988, Lamberts *et al.* 1991). In view of the ability of somatostatin to inhibit such a variety of physiological processes, it was predicted that this peptide might be of therapeutic value in

clinical conditions involving hyperfunction or hypersecretion of the organ systems mentioned above. However, the multiple simultaneous effects of pharmacological concentrations of somatostatin in different organs, the need for intravenous administration, the short duration of action (a half-life in the circulation of less than 3 min) and the post-infusion rebound hypersecretion of hormones considerably hampered the initial enthusiasm, as well as its clinical use (Lamberts *et al.* 1996).

Somatostatin receptor subtypes

Somatostatin-14 and somatostatin-28 act through high-affinity G protein-coupled membrane receptors. Five somatostatin receptor (sst) subtype genes have been cloned and characterised. They were code-named sst₁, sst₂, sst₃, sst₄ and sst₅ (Hoyer *et al.* 1994). The genes encoding the five sst subtypes are localised on different chromosomes (Patel 1997). Two forms of the sst₂ receptor (sst_{2A} and sst_{2B}) can be generated through alternative splicing (Vanetti *et al.* 1992, Patel *et al.* 1993). Upon binding of somatostatin to its receptor subtype(s) second messenger systems will become activated.

Table 1 Binding affinities of somatostatin analogues to the five sst subtypes (Bruns *et al.* 2002). Values are means ± s.e.m.

Compound	IC ₅₀ value (nM)				
	sst ₁	sst ₂	sst ₃	sst ₄	sst ₅
Somatostatin 14	0.93 ± 0.12	0.15 ± 0.02	0.56 ± 0.17	1.5 ± 0.4	0.29 ± 0.04
Lanreotide	180 ± 20	0.54 ± 0.08	14 ± 9	230 ± 40	17 ± 5
Octreotide	280 ± 80	0.38 ± 0.08	7.1 ± 1.4	>1000	6.3 ± 1.0
Chromosomal location	14	17	22	20	16

These systems include (1) inhibition of adenylate cyclase activity and (2) activity of calcium channels, as well as (3) stimulation of phosphotyrosine phosphatase or (4) MAP (mitogen-activated protein) kinase activity (Reisine & Bell 1995, Patel 1997, 1999). The inhibitory effects of somatostatin on adenylate cyclase activity and on the influx of calcium are linked to inhibition of secretion processes. The activation of phosphotyrosine phosphatase or MAP kinase activity by somatostatin may play a role in the regulation of cell proliferation (Schally 1988, Lamberts *et al.* 1991, Hofland *et al.* 1995).

Classical somatostatin-target tissues such as the central nervous system, the anterior pituitary gland and the pancreas express multiple sst subtypes. Pancreatic islet cells express all five sst subtype proteins (Reubi *et al.* 1998b, Kumar *et al.* 1999). In these cells, sst₁, sst₂ and sst₅ receptors are the most abundantly expressed subtypes, with a high percentage of β-cells expressing sst₁ and sst₅, α-cells expressing sst₂ and δ-cells expressing sst₅ (Kumar *et al.* 1999).

Tumours arising from somatostatin-target tissues frequently express a high density of ssts (Reubi *et al.* 1992a,b, 1994, 1996, 2001). The sst-expressing tumours include pituitary adenomas, pancreatic endocrine tumours, carcinoids, paragangliomas, pheochromocytomas, small cell lung cancers, medullary thyroid carcinomas, breast cancers and malignant lymphomas (Reubi *et al.* 1992b, Vikic-Topic *et al.* 1995). The sst subtype expression in different tumours has been demonstrated at the mRNA level using *in situ* hybridisation, RNase protection assays and RT-PCR (Kubota *et al.* 1994, Panetta & Patel 1995). The majority of sst-positive tumours simultaneously express multiple sst subtypes, although there is a considerable variation in sst subtype expression between the different tumour types and among tumours of the same type (Reubi *et al.* 1998a, Schulz *et al.* 1998, Kimura *et al.* 1999, Hofland *et al.* 1999b). Endocrine pancreatic and endocrine digestive tract tumours can also express multiple sst subtypes, but sst₂ predominance is generally found in more than 80% (Reubi *et al.* 1994, 2001, de Herder *et al.* 1996a, Papotti *et al.* 2002, Reubi & Waser 2003).

The five sst subtypes all bind somatostatin-14 and somatostatin-28 with high affinity. The sst₁ and sst₄ receptors do not bind the currently available octapeptide somatostatin analogues octreotide and lanreotide (see later), whereas sst_{2A}, sst₃ and sst₅ receptors display a high, low, and moderate affinity

respectively towards these octapeptide somatostatin analogues (Table 1). The predominant expression of sst₂ receptors on pancreatic endocrine or carcinoid tumours forms the basis for the successful clinical application of octapeptide somatostatin analogues such as octreotide and lanreotide in controlling symptoms related to hormonal hypersecretion (Lamberts *et al.* 1996, de Herder *et al.* 1996b, de Herder & Lamberts 2002). The high density of sst subtypes on these tumours further allows the use of radiolabelled somatostatin analogues to visualise sst-positive tumours *in vivo* (see later) (Krenning *et al.* 1992, 1993, 1994a,b, 1999, Kwekkeboom *et al.* 1993, Kwekkeboom & Krenning 1996). Therefore, knowledge of the sst subtype expression patterns in endocrine tumours may be very important for the development of the concept of sst-targeted radiotherapy or chemotherapy (see later).

Also, ssts may form homo- or heterodimers or may heterodimerise with other G protein-coupled receptors such as the dopamine D₂ receptor or the μ-opioid receptor (MOR-1), resulting in a novel receptor state with properties different from the individual receptors (Rocheville *et al.* 2000a,b, Pfeiffer *et al.* 2001, 2002).

Somatostatin analogues

As mentioned above, there are several limitations to the use of native somatostatin-14 and -28 in daily practice. Therefore, attempts have been made to synthesise somatostatin analogues for clinical use. Octreotide (Sandostatin, Novartis, Basel, Switzerland) was the first octapeptide somatostatin analogue that was synthesised. Its elimination half-life after subcutaneous administration is 2 h, and rebound hypersecretion of hormones does not occur (Bauer *et al.* 1982). Somatostatin and its analogues exert their effects through interaction with sst subtypes 1 through 5 (sst₁₋₅). Somatostatin binds with high affinity to all somatostatin subtypes, whereas octreotide binds only with a high affinity to sst₂ and sst₅ (Patel 1999). Other cyclic analogues with almost similar affinity and activity profiles, such as lanreotide (Somatuline, Ipsen Biotech, Paris, France) have been subsequently developed (Lamberts *et al.* 1996). Octreotide (Sandostatin) and lanreotide (Somatuline) have been registered in most countries for the control of hormonal symptoms in patients with carcinoids and endocrine pancreatic tumours and in patients with acromegaly. Octreotide and lanreotide can be administered by

multiple subcutaneous injections or by continuous subcutaneous infusion as well as by the intravenous route, either as a single injection or as a continuous infusion over many hours or days. The slow-release depot intramuscular formulation of octreotide (Sandostatin LAR, Novartis Pharma, Basel, Switzerland) has to be administered once every 4 weeks and that of lanreotide (Somatuline-PR, Ipsen Biotech, Paris, France) once every 2 weeks. A new slow-release depot preparation of lanreotide, Lanreotide Autogel (Ipsen Biotech, Paris France), has been introduced in several European countries. This drug has to be administered deep subcutaneously once every 4 weeks.

In the majority of patients with metastatic carcinoids and pancreatic endocrine tumours, treatment with octreotide induces a rapid improvement of clinical symptomatology, such as diarrhoea, dehydration, flushing attacks, hypokalaemia, peptic ulceration, hypoglycaemic attacks and necrotic skin lesions (Kvols *et al.* 1986, 1987, Ruzsniowski *et al.* 1996, Caplin *et al.* 1998, Kulke & Mayer 1999, Wymenga *et al.* 1999). On the other hand, the majority of these patients show desensitisation of the inhibition of hormone secretion by octreotide and lanreotide within weeks to months. In a series of 57 patients with the carcinoid syndrome, octreotide therapy was ended in 23 patients after periods ranging from 1 week to 12.5 months (median 4 months), whereas the other responding patients could be controlled for periods extending to 2.5 years. The estimated mean duration of response to octreotide therapy in the whole group of responding patients was approximately 1 year (Moertel 1987). The potential mechanisms responsible for this desensitisation, as well as for the considerable variability in the duration of the responses to octreotide therapy are not known at present. Potential mechanisms of tachyphylaxis and resistance to somatostatin analogue therapy in patients with sst-positive tumours are (1) receptor down-regulation; a decrease in the number and/or affinity of ssts, (2) desensitisation; a decrease in responsiveness due to receptor uncoupling from second messenger activation, (3) non-homogeneous expression of ssts in tumours, (4) outgrowth of sst-negative cell clones, (5) resistance due to the absence of sst subtypes with high affinity for octapeptide somatostatin analogues, (6) resistance due to tachyphylaxis of the inhibitory effect of somatostatin analogues on indirect tumour growth-promoting mechanisms (like growth hormone or gastrin) and (7) mutations in sst genes leading to the absence of functional receptor proteins (Lamberts *et al.* 1988, Hofland & Lamberts 2003).

Expression of ssts by endocrine tumours is essential for the control of hormonal hypersecretion by the octapeptide somatostatin analogues. Somatostatin is also able to inhibit proliferation of normal and tumour cells. Induction of G1 cell arrest and induction of apoptosis have been demonstrated in a number of tumour cell models and several sst subtypes seem to be involved (Buscail *et al.* 1994, 1995, Cordelier *et al.* 1997, Alderton *et al.* 1998, Bousquet *et al.* 1998, 2001,

Sharma & Srikant 1998, Sharma *et al.* 1999, Pages *et al.* 1999, Rochaix *et al.* 1999, Benali *et al.* 2000, Vernejoul *et al.* 2002b). Various reports demonstrating tumour regression or stabilisation in patients with metastatic carcinoids and endocrine tumours of the gastrointestinal tract with octapeptide somatostatin analogues are consistent with these experimental data although other mechanisms may also play a role, such as inhibition of angiogenesis and inhibition of growth factors by these drugs (Kraenzlin *et al.* 1983, Clements & Elias 1985, Wiedenmann *et al.* 1988, Woltering *et al.* 1997, Filosso *et al.* 2000, Imtiaz *et al.* 2000, Delle Fave & Corleto 2001, Garcia de la Torre *et al.* 2002, Shojamanesh *et al.* 2002, Florio *et al.* 2003).

sst scintigraphy

Tumours and metastases that bear sst₂ or sst₅ can be visualised *in vivo* after injection of radiolabelled octapeptide analogues. The technique of sst scintigraphy to visualise sst-positive tumours in man was first developed using the radiolabelled somatostatin analogue [¹²³I-Tyr³]octreotide (Krenning *et al.* 1989). Because the use of this radiopharmaceutical had a number of drawbacks (such as costs, lack of availability, short physical half-life and predominant hepatic clearance resulting in accumulation of radioactivity in liver, gall bladder, bile ducts and gastrointestinal tract), novel somatostatin analogues were developed to circumvent these disadvantages. The most widely used somatostatin analogue for sst scintigraphy is currently ¹¹¹In-pentetreotide ([¹¹¹In-DTPA⁰]octreotide, OctreoScan, Tyco Healthcare, Mallickrodt, St Louis, USA) (Krenning *et al.* 1993). Apart from ¹¹¹In-pentetreotide, [¹¹¹In-DOTA⁰]lanreotide can also be used (Krenning *et al.* 1994b, Virgolini *et al.* 2001).

sst targeted radiotherapy

In general, sst-agonist complexes follow the mechanism and route of internalisation as described for many other G protein-coupled receptor complexes (Hausdorff *et al.* 1990, Yu *et al.* 1993, Roettger *et al.* 1995, Ferguson *et al.* 1996, Koenig & Edwardson 1997, Hofland & Lamberts 2003). The sst subtypes differentially internalise somatostatin and somatostatin analogues. The sst₁ receptors show low agonist-induced internalisation, whereas sst₂, sst₃, sst₄ and sst₅ are more efficient in this respect (Patel 1999, Hofland & Lamberts 2003).

In tumour tissue obtained after the administration of [¹¹¹In-DTPA⁰]octreotide to patients harbouring Octreoscan-positive metastatic midgut carcinoids, the subcellular distribution of radioactivity using ultrastructural autoradiography was subsequently analysed. This radioactivity could be found at the plasma membrane, in the cytoplasmic areas among secretory granules and vesicular compartments, but also in the perinuclear area. This localisation of ¹¹¹In in close prox-

imity to the cell nucleus is especially important for this short range Auger electron-emitting radioisotope to exert its cytotoxic effect in the form of DNA double-strand damage (Janson *et al.* 2000). The predominant expression of sst₂ receptors in most sst-positive endocrine tumours and the efficiency of sst₂ receptors to undergo agonist-induced internalisation is very important for the application of sst-targeted radiotherapy. However, [¹¹¹In-DTPA⁰]octreotide may not be the most suitable compound to carry out radiotherapy because the Auger electron-emitter ¹¹¹In has a low tissue penetration. In addition, a stable coupling of α- or β-emitting isotopes to [DTPA⁰]octreotide could not be achieved, which initiated the development of a novel compound, such as [DOTA⁰,Tyr³]octreotide, allowing a stable binding with the β-emitter yttrium-90 (⁹⁰Y) [⁹⁰Y-DOTA⁰,Tyr³]octreotide (OctreoTher, Novartis Pharma, Basel, Switzerland) and lutetium 177 ([¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate). Furthermore, [¹¹¹In-DOTA⁰]lanreotide and [⁹⁰Y-DOTA⁰]lanreotide can also be used for radiotherapy of sst₂- and sst₅-positive advanced or metastatic endocrine tumours (Hofland *et al.* 1999a, Anthony *et al.* 2002, Kwekkeboom *et al.* 2002, 2003, Valkema *et al.* 2002a,b, Virgolini *et al.* 2002).

Several mechanisms may determine the amount of uptake of radiolabelled somatostatin analogues. These include: (1) the stability of the radioligand, (2) the density of sst expression on the tumour, (3) the type of ssts expressed by the tumour, (4) affinity of the radioligand for the sst, (5) the efficiency of sst-mediated internalisation and recycling, (6) the final trapping of the radioisotopes within the tumour cells, as well as (7) the mass of the injected peptide (Nouel *et al.* 1997, Hukovic *et al.* 1999, Hofland 1999a, Hofland & Lamberts 2003).

New developments

Because every sst has distinct biologic functions, the development of new classes of somatostatin subtype-selective analogues may provide valuable information for tumour diagnosis, prognosis and prediction of somatostatin analogue efficacy, not only in tumours that are sensitive to the currently available octapeptide analogues, but also in tumours that express ssts other than sst₂ and sst₅. A new so-called 'universal' somatostatin analogue, named SOM230, with high affinity for sst₁, sst₂, sst₃ and sst₅ receptors is currently under evaluation in phase I–III trials (Bruns *et al.* 2002, Lamberts *et al.* 2002, Weckbecker *et al.* 2002). New drugs interacting with multi-receptor family cross-talk are being developed. These sst subtype homo- or heterodimers may have properties which are distinct from the individual receptors in terms of internalisation, agonist-induced desensitisation and functional activity (Rocheville *et al.* 2000a,b, Pfeiffer *et al.* 2001, 2002). The hybrid somatostatin–dopamine molecule, BIM-23A387, has high-affinity binding to both sst₂

and dopamine D₂ receptors and has an enhanced potency on growth hormone and prolactin release by primary cultures of pituitary adenoma cells, compared with sst₂- and D₂-specific analogues alone or in combination. This significant enhanced potency, however, cannot be explained on the basis of the binding affinity of the compounds for sst₂ and dopamine D₂ receptors (Saveanu *et al.* 2002).

Like peptide receptor-targeted radiotherapy, targeted chemotherapy to deliver the chemotherapeutic compounds selectively to tumour cells might be a promising approach as well (Plonowski *et al.* 2000, 2001, 2002, Kiaris *et al.* 2001). Although still at a very early stage, gene therapy may represent an exciting new treatment alternative for patients with advanced tumours. Transfer of genes that encode for the expression of sst₂ to sst-negative cancers may render these tumours responsive to the currently available (radiolabelled or cytotoxic) octapeptide somatostatin analogues (Benali *et al.* 2000, Vernejoul *et al.* 2002, Guillermet *et al.* 2003).

References

- Alderton F, Fan TP, Schindler M & Humphrey PP 1998 Rat somatostatin sst2(a) and sst2(b) receptor isoforms mediate opposite effects on cell proliferation. *British Journal of Pharmacology* **125** 1630–1633.
- Anthony LB, Woltering EA, Espenan GD, Cronin MD, Maloney TJ & McCarthy KE 2002 Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. *Seminars in Nuclear Medicine* **32** 123–132.
- Bauer W, Briner U, Doeppner W, Haller R, Huguenin R, Marbach P, Petcher TJ & Pless J 1982 SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. *Life Sciences* **31** 1133–1140.
- Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A, Esteve JP, Pour PM, Schally AV, Vaysse N, Susini C & Buscail L 2000 Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. *PNAS* **97** 9180–9185.
- Bousquet C, Delesque N, Lopez F, Saint-Laurent N, Esteve JP, Bedecs K, Buscail L, Vaysse N & Susini C 1998 sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1. *Journal of Biological Chemistry* **273** 7099–7106.
- Bousquet C, Puente E, Buscail L, Vaysse N & Susini C 2001 Antiproliferative effect of somatostatin and analogs. *Chemotherapy* **47** (Suppl 2) 30–39.
- Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J & Guillemin R 1973 Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. *Science* **179** 77–79.
- Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. *European Journal of Endocrinology* **146** 707–716.
- Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C & Schally AV 1994 Stimulation of tyrosine phosphatase and inhibition of cell

- proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. *PNAS* **91** 2315–2319.
- Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N & Susini C 1995 Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. *PNAS* **92** 1580–1584.
- Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF & Burroughs AK 1998 Carcinoid tumour. *Lancet* **352** 799–805.
- Clements D & Elias E 1985 Regression of metastatic vipoma with somatostatin analogue SMS 201-995. *Lancet* **i** 874–875.
- Cordelier P, Esteve JP, Bousquet C, Delesque N, O'Carroll AM, Schally AV, Vaysse N, Susini C & Buscail L 1997 Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. *PNAS* **94** 9343–9348.
- Delle Fave GF & Corleto VD 2001 Oncogenes, growth factors, receptor expression and proliferation markers in digestive neuroendocrine tumours. A critical reappraisal. *Annals of Oncology* **12** (Suppl 2) S13–S17.
- Ferguson SS, Barak LS, Zhang J & Caron MG 1996 G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. *Canadian Journal of Physiology and Pharmacology* **74** 1095–1110.
- Filosso PL, Croce S, Oliaro A & Ruffini E 2000 Long-term survival of patients treated with octreotide for metastatic well differentiated neuroendocrine carcinoma of the lung. *Journal of Cardiovascular Surgery* **41** 773–776.
- Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G & Albini A 2003 Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. *Endocrinology* **144** 1574–1584.
- Garcia de la Torre N, Wass JA & Turner HE 2002 Antiangiogenic effects of somatostatin analogues. *Clinical Endocrinology* **57** 425–441.
- Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, Pradayrol L, Buscail L, Susini C & Bousquet C 2003 Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. *PNAS* **100** 155–160.
- Hausdorff WP, Caron MG & Lefkowitz RJ 1990 Turning off the signal: desensitization of beta-adrenergic receptor function. *FASEB Journal* **4** 2881–2889.
- de Herder WW & Lamberts SW 2002 Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. *Current Opinion in Oncology* **14** 53–57.
- de Herder WW, Hofland LJ, van der Lely AJ & Lamberts SW 1996a Peptide receptors in gut endocrine tumours. *Bailliere's Clinical Gastroenterology* **10** 571–587.
- de Herder WW, van der Lely AJ & Lamberts SW 1996b Somatostatin analogue treatment of neuroendocrine tumours. *Postgraduate Medical Journal* **72** 403–408.
- Hofland LJ & Lamberts SW 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance. *Endocrine Reviews* **24** 28–47.
- Hofland LJ, Visser-Wisselaar HA & Lamberts SW 1995 Somatostatin analogs: clinical application in relation to human somatostatin receptor subtypes. *Biochemical Pharmacology* **50** 287–297.
- Hofland LJ, Breeman WA, Krenning EP, de Jong M, Waaijers M, van Koetsveld PM, Macke HR & Lamberts SW 1999a Internalization of [DOTA⁰,¹²⁵I-Tyr³]octreotide by somatostatin receptor-positive cells *in vitro* and *in vivo*: implications for somatostatin receptor-targeted radio-guided surgery. *Proceedings of the Association of American Physicians* **111** 63–69.
- Hofland LJ, Liu Q, van Koetsveld PM, Zuijderwijk J, van der Ham F, de Krijger RR, Schonbrunn A & Lamberts SW 1999b Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. *Journal of Clinical Endocrinology and Metabolism* **84** 775–780.
- Hoyer D, Lubbert H & Bruns C 1994 Molecular pharmacology of somatostatin receptors. *Naunyn Schmiedeberg's Archives of Pharmacology* **350** 441–453.
- Hukovic N, Rocheville M, Kumar U, Sasi R, Khare S & Patel YC 1999 Agonist-dependent up-regulation of human somatostatin receptor type 1 requires molecular signals in the cytoplasmic C-tail. *Journal of Biological Chemistry* **274** 24550–24558.
- Imtiaz KE, Monteith P & Khaleeli A 2000 Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. *Clinical Endocrinology* **53** 755–758.
- Janson ET, Westlin JE, Ohrvall U, Oberg K & Lukinius A 2000 Nuclear localization of ¹¹¹In after intravenous injection of [¹¹¹In-DTPA-D-Phe¹]-octreotide in patients with neuroendocrine tumors. *Journal of Nuclear Medicine* **41** 1514–1518.
- Kiaris H, Schally AV, Nagy A, Szepeshazi K, Hebert F & Halmos G 2001 A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. *European Journal of Cancer* **37** 620–628.
- Kimura N, Pilichowska M, Date F, Kimura I & Schindler M 1999 Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. *Clinical Cancer Research* **5** 3483–3487.
- Koenig JA & Edwardson JM 1997 Endocytosis and recycling of G protein-coupled receptors. *Trends in Pharmacological Sciences* **18** 276–287.
- Kraenzlin ME, Ch'ng JC, Wood SM & Bloom SR 1983 Can inhibition of hormone secretion be associated with endocrine tumour shrinkage? *Lancet* **ii** 1501.
- Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, Lameris JS, Reubi JC & Lamberts SW 1989 Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. *Lancet* **i** 242–244.
- Krenning EP, Kwekkeboom DJ, Oei HY, Reubi JC, van Hagen PM, Kooij PP, Reijs AE & Lamberts SW 1992 Somatostatin receptor imaging of endocrine gastrointestinal tumors. *Schweizerische Medizinische Wochenschrift* **122** 634–637.
- Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M & Reubi JC 1993 Somatostatin receptor scintigraphy with [¹¹¹In-DTPA-D-Phe¹]- and [¹²³I-Tyr³]-octreotide: the Rotterdam experience with more than 1000 patients. *European Journal of Nuclear Medicine* **20** 716–731.
- Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, de Herder WW, Reubi JC & Lamberts SW 1994a Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome. *Digestion* **55** (Suppl 3) 54–59.
- Krenning EP, Kwekkeboom DJ, Oei HY, de Jong RJ, Dop FJ, Reubi JC & Lamberts SW 1994b Somatostatin-receptor

- scintigraphy in gastroenteropancreatic tumors. An overview of European results. *Annals of the New York Academy of Sciences* **733** 416–424.
- Krenning EP, Valkema R, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, de Jong M & Pauwels S 1999 Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-βEd-Phe1]-octreotide. *Italian Journal of Gastroenterology and Hepatology* **31** (Suppl 2) S219–S223.
- Krulich L, Dhariwal AP & McCann SM 1968 Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary *in vitro*. *Endocrinology* **83** 783–790.
- Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S & Seino Y 1994 Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. *Journal of Clinical Investigation* **93** 1321–1325.
- Kulke MH & Mayer RJ 1999 Carcinoid tumors. *New England Journal of Medicine* **340** 858–868.
- Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC & Patel, YC 1999 Subtype-selective expression of the five somatostatin receptors (hSSTR1–5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. *Diabetes* **48** 77–85.
- Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J & Hahn RG 1986 Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. *New England Journal of Medicine* **315** 663–666.
- Kvols LK, Buck M, Moertel CG, Schutt AJ, Rubin J, O'Connell MJ & Hahn RG 1987 Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). *Annals of Internal Medicine* **107** 162–168.
- Kwekkeboom DJ & Krenning EP 1996 Somatostatin receptor scintigraphy in patients with carcinoid tumors. *World Journal of Surgery* **20** 157–161.
- Kwekkeboom DJ, Krenning EP, Bakker WH, Oei HY, Kooij PP & Lamberts SW 1993 Somatostatin analogue scintigraphy in carcinoid tumours. *European Journal of Nuclear Medicine* **20** 283–292.
- Kwekkeboom DJ, Kam BL, Bakker WH, Kooij PP, de Herder WW, Srinivasan S, Erion JL, Bugaj JL, Schmidt MA, de Jong M & Krenning EP 2002 Treatment with Lu-177-DOTA-Tyr³-octreotate in patients with somatostatin receptor positive tumors. *Journal of Nuclear Medicine* **43** (Suppl 5) 34P.
- Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, de Jong M, Srinivasan A, Erion JL & Krenning EP 2003 Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate. *European Journal of Nuclear Medicine and Molecular Imaging* **30** 417–422.
- Lamberts SW, Pieters GF, Metselaar HJ, Ong GL, Tan HS & Reubi JC 1988 Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. *Acta Endocrinologica* **119** 561–566.
- Lamberts SW, Krenning EP & Reubi JC 1991 The role of somatostatin and its analogs in the diagnosis and treatment of tumors. *Endocrine Reviews* **12** 450–482.
- Lamberts SW, van der Lely AJ, de Herder WW & Hofland LJ 1996 Octreotide. *New England Journal of Medicine* **334** 246–254.
- Lamberts SW, van der Lely AJ & Hofland LJ 2002 New somatostatin analogs: will they fulfil old promises? *European Journal of Endocrinology* **146** 701–705.
- Moertel CG 1987 Karnofsky memorial lecture. An odyssey in the land of small tumors. *Journal of Clinical Oncology* **5** 1502–1522.
- Noel D, Gaudriault G, Houle M, Reisine T, Vincent JP, Mazella J & Baudet A 1997 Differential internalization of somatostatin in COS-7 cells transfected with SST1 and SST2 receptor subtypes: a confocal microscopic study using novel fluorescent somatostatin derivatives. *Endocrinology* **138** 296–306.
- Pages P, Benali N, Saint-Laurent N, Esteve JP, Schally AV, Tkaczuk J, Vaysse N, Susini C & Buscail L 1999 sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. *Journal of Biological Chemistry* **274** 15186–15193.
- Panetta R & Patel YC 1995 Expression of mRNA for all five human somatostatin receptors (hSSTR1–5) in pituitary tumors. *Life Sciences* **56** 333–342.
- Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, Schindler M, Cole SL & Bussolati G 2002 Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. *Virchows Archiv* **440** 461–475.
- Patel YC 1997 Molecular pharmacology of somatostatin receptor subtypes. *Journal of Endocrinological Investigation* **20** 348–367.
- Patel YC 1999 Somatostatin and its receptor family. *Frontiers in Neuroendocrinology* **20** 157–198.
- Patel YC, Greenwood M, Kent G, Panetta R & Srikant CB 1993 Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. *Biochemical and Biophysical Research Communications* **192** 288–294.
- Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp HJ, Holt V & Schulz S 2001 Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). *Journal of Biological Chemistry* **276** 14027–14036.
- Pfeiffer M, Koch T, Schroder H, Laugsch M, Holt V & Schulz S 2002 Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. *Journal of Biological Chemistry* **277** 19762–19772.
- Plonowski A, Schally AV, Nagy A, Kiaris H, Hebert F & Halmos G 2000 Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238. *Cancer Research* **60** 2996–3001.
- Plonowski A, Schally AV, Koppan M, Nagy A, Arencibia JM, Csernus B & Halmos G 2001 Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. *Cancer* **92** 1168–1176.
- Plonowski A, Schally AV, Nagy A, Sun B & Halmos G 2002 Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238. *International Journal of Oncology* **20** 397–402.
- Reichlin S 1983a Somatostatin. *New England Journal of Medicine* **309** 1495–1501.
- Reichlin S 1983b Somatostatin (second of two parts). *New England Journal of Medicine* **309** 1556–1563.

- Reisine T & Bell GI 1995 Molecular biology of somatostatin receptors. *Endocrine Reviews* **16** 427–442.
- Reubi JC & Waser B 2003 Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for *in vivo* multireceptor tumour targeting. *European Journal of Nuclear Medicine and Molecular Imaging* **30** 781–793.
- Reubi JC, Kappeler A, Waser B, Laissue J, Hipkin RW & Schonbrunn A 1998a Immunohistochemical localization of somatostatin receptors sst2A in human tumors. *American Journal of Pathology* **153** 233–245.
- Reubi JC, Kappeler A, Waser B, Schonbrunn A & Laissue J 1998b Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. *Journal of Clinical Endocrinology and Metabolism* **83** 3746–3749.
- Reubi JC, Krenning E, Lamberts SW & Kvols L 1992a *In vitro* detection of somatostatin receptors in human tumors. *Metabolism* **41** 104–110.
- Reubi JC, Laissue J, Krenning E & Lamberts SW 1992b Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. *Journal of Steroid Biochemistry and Molecular Biology* **43** 27–35.
- Reubi JC, Laissue J, Waser B, Horisberger U & Schaer JC 1994 Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. *Annals of the New York Academy of Sciences* **733** 122–137.
- Reubi JC, Schaer JC, Laissue JA & Waser B 1996 Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. *Metabolism* **45** 39–41.
- Reubi JC, Waser B, Schaer JC & Laissue JA 2001 Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. *European Journal of Nuclear Medicine* **28** 836–846.
- Rochaix P, Delesque N, Esteve JP, Saint-Laurent N, Voight JJ, Vaysse N, Susini C & Buscail L 1999 Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. *Human Gene Therapy* **10** 995–1008.
- Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC & Patel YC 2000a Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. *Science* **288** 154–157.
- Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC & Patel YC 2000b Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. *Journal of Biological Chemistry* **275** 7862–7869.
- Roettger BF, Rentsch RU, Pinon D, Holicky E, Hadac E, Larkin JM & Miller LJ 1995 Dual pathways of internalization of the cholecystokinin receptor. *Journal of Cell Biology* **128** 1029–1041.
- Ruszniewski P, Ducreux M, Chayvialle JA, Blumberg J, Cloarec D, Michel H, Raymond JM, Dupas JL, Gouerou H, Jian R, Genestin E, Bernades P & Rougier P 1996 Treatment of the carcinoid syndrome with the long acting somatostatin analogue lanreotide: a prospective study in 39 patients. *Gut* **39** 279–283.
- Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A & Jaquet P 2002 Demonstration of enhanced potency of a chimeric somatostatin–dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. *Journal of Clinical Endocrinology and Metabolism* **87** 5545–5552.
- Schally AV 1988 Oncological applications of somatostatin analogues. *Cancer Research* **48** 6977–6985.
- Schulz S, Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, Weise W, Roessner A, Gramsch C & Holtt V 1998 Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. *Clinical Cancer Research* **4** 2047–2052.
- Sharma K & Srikant CB 1998 Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. *International Journal of Cancer* **76** 259–266.
- Sharma K, Patel YC & Srikant CB 1999 C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. *Molecular Endocrinology* **13** 82–90.
- Shojamanesh H, Gibril F, Louie A, Ojeaburu JV, Bashir S, Abou-Saif A & Jensen RT 2002 Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma. *Cancer* **94** 331–343.
- Valkema R, de Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, de Jong FH, Christiansen A, Kam BL, de Herder WW, Stridsberg M, Lindemans J, Ensing G & Krenning EP 2002a Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. *Seminars in Nuclear Medicine* **32** 110–122.
- Valkema R, Kvols LK, Jamar F, Bakker WH, Smith C, Krenning EP & Pauwels S 2002b Phase I study of therapy with 90Y-SMT 487 (OctreoTher) in patients with somatostatin receptor (SS-R) positive tumors. *Journal of Nuclear Medicine* **43** (Suppl 5) 33P.
- Vanetti M, Kouba M, Wang X, Vogt G & Holtt V 1992 Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). *FEBS Letters* **311** 290–294.
- Vernejoul F, Faure P, Benali N, Calise D, Tiraby G, Pradayrol L, Susini C & Buscail L 2002 Antitumor effect of *in vivo* somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. *Cancer Research* **62** 6124–6131.
- Vikic-Topic S, Raisch KP, Kvols LK & Vuk-Pavlovic S 1995 Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. *Journal of Clinical Endocrinology and Metabolism* **80** 2974–2979.
- Virgolini I, Patri P, Novotny C, Traub T, Leimer M, Fuger B, Li SR, Angelberger P, Raderer M, Wogritsch S, Kurtaran A, Kletter K & Dudczak R 2001 Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. *Annals of Oncology* **12** (Suppl 2) S41–S45.
- Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G & Riva P 2002 In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. *Seminars in Nuclear Medicine* **32** 148–155.
- Weckbecker G, Briner U, Lewis I & Bruns C 2002 SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. *Endocrinology* **143** 4123–4130.
- Wiedenmann B, Rath U, Radsch R, Becker F & Kommerell B 1988 Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995. *Klinische Wochenschrift* **66** 75–77.

- Woltering EA, Watson JC, Alperin-Lea RC, Sharma C, Keenan E, Kurozawa D & Barrie R 1997 Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. *Investigational New Drugs* **15** 77–86.
- Wymenga AN, Eriksson B, Salmela PI, Jacobsen MB, van Cutsem EJ, Fiasse RH, Valimaki MJ, Renstrup J, de Vries EG & Oberg KE 1999 Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. *Journal of Clinical Oncology* **17** 1111–1117.
- Yu SS, Lefkowitz RJ & Hausdorff WP 1993 Beta-adrenergic receptor sequestration. A potential mechanism of receptor resensitization. *Journal of Biological Chemistry* **268** 337–341.